Drugs / CLSP-1025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06778863 | Feb 2025 → Dec 2027 expected | breast cancer, colorectal adenocarcinoma, head and neck squamous cell carcinoma, lung cancer +5 | Clasp Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | Clasp Therapeutics, Inc. | Results Clasp Therapeutics Publishes Preclinical Data on CLSP-1025, the First Clinical-Stage T-Cell Engager Targeting an Intracellular Driver Mutation, in Clinical Cancer Research clasptx.com ↗
Data demonstrate potent, mutation-specific anti-tumor activity with extensive characterization of selectivity and safety |
| 2025-04-28 | Clasp Therapeutics, Inc. | Results Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting clasptx.com ↗
Preclinical studies show that CLSP-1025 induces robust, targeted T cell activation, resulting in significant regression of KMS-26 tumor xenografts in vivo. |
| 2024-11-07 | Clasp Therapeutics, Inc. | Results Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting clasptx.com ↗
Clasp-1025, Clasp’s first-in-class T cell engager (TCE) targeting mutant p53, demonstrates selectivity, sensitivity and activity across preclinical models |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-24 | Clasp Therapeutics, Inc. | Clasp Therapeutics Publishes Preclinical Data on CLSP-1025, the First Clinical-Stage T-Cell Engager Targeting an Intracellular Driver Mutation, in Clinical Cancer Research clasptx.com ↗ |
| 2025-04-28 | Clasp Therapeutics, Inc. | Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting clasptx.com ↗ |
| 2024-11-07 | Clasp Therapeutics, Inc. | Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting clasptx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLSP-1025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06778863 ↗ |
| Modality | Other / unclassified | “T cell engager (TCE)” NCT06778863 ↗ |
| Route | Intravenous | “CLSP-1025 will be administered by IV infusion” NCT06778863 ↗ |